NASDAQ:CLDX

Celldex Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CLDX

*Your capital is at risk

$39.11

+0.130 (+0.334%)

At Close: Jul 10, 2026

Celldex Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 77.43. In total, the insiders bought 4.34M and sold 170.35K CLDX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	77.43
● Buy	4.34M shares
● Sell	170.35K shares
88% Buy Activity Strong Negative Correlation
Buy Signal High Confidence Jun 25, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 77.43. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (88% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Conrad Herbert J Director	Director	26 000 Value: $886.3K
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Brownlie Keith L Director	Director	26 000 Value: $886.3K
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Cohen Cheryl Director	Director	26 000 Value: $886.3K
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Jain Rita Director	Director	26 000 Value: $886.3K
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Torres Denice Director	Director	26 000 Value: $886.3K
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Keler Tibor Executive Vp & Cso	Officer	115 000 Value: $3.92M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Pepin Ronald Sr. Vp & Cbo	Officer	20 000 Value: $681.8K
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Cavanaugh Sarah SVP Of Corp Affairs & Admin.	Officer	95 000 Value: $3.24M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Heath-chiozzi Margo SVP Of Regulatory Affairs	Officer	95 000 Value: $3.24M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Jimenez Freddy A. SVP & General Counsel	Officer	93 000 Value: $3.17M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Lawver Teri L SVP & Chief Commercial Officer	Officer	90 000 Value: $3.07M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Young Diane C. SVP, Chief Medical Officer	Officer	57 000 Value: $1.94M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Martin Samuel Bates SVP And CFO	C-Suite Officer	93 000 Value: $3.17M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Crowley Elizabeth Sr. Vp & Cpdo	Officer	100 000 Value: $3.41M
Jun 25, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Marucci Anthony S President & CEO	CEO / President	375 000 Value: $12.8M
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Neil Garry Arthur Director	Director	26 000 Value: $886.3K
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Marino James J Director	Director	26 000 Value: $886.3K
Jun 25, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Penner Harry Jr Director	Director	26 000 Value: $886.3K
Jan 02, 2026 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	4 817 Value: $50.0K
Jan 02, 2026 Buy	Common Stock M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	4 817 Value: $50.0K
Dec 15, 2025 Buy	Incentive Stock Option (right to buy) M-Exempt	Pepin Ronald Sr. Vp & Cbo	Officer	11 000 Value: $30.6K
Dec 15, 2025 Buy	Common Stock M-Exempt	Pepin Ronald Sr. Vp & Cbo	Officer	8 333 Value: $75.1K
Dec 15, 2025 Buy	Common Stock M-Exempt	Pepin Ronald Sr. Vp & Cbo	Officer	11 000 Value: $30.6K
Dec 15, 2025 Buy	Incentive Stock Option (right to buy) M-Exempt	Pepin Ronald Sr. Vp & Cbo	Officer	8 333 Value: $75.1K
Dec 04, 2025 Sell	Common Stock S-Sale	Jimenez Freddy A. SVP & General Counsel	Officer	4 166 Value: $121.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CELLDEX THERAPEUTICS

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity...

Read Full Profile Here